Related Experiment Video

Updated: Jun 4, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
07:22

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion

Published on: August 14, 2018

Evaluation of Compounds That Prevent Reactivation of HIV-1 in OM-10.1 Cells

S T Butera

    Methods in Molecular Medicine
    |February 19, 2011
    PubMed

    Insights

    Identifying new human immunodeficiency virus type 1 (HIV-1) therapies is crucial. Current pre-integration treatments show limited success, but chemokine-mediated fusion suppression offers new therapeutic avenues.

    Area of Science:

    • Virology
    • Immunology
    • Drug Discovery

    Background:

    • Current human immunodeficiency virus type 1 (HIV-1) therapies primarily target viral factors before proviral integration.
    • Preintegrative therapeutic strategies, including reverse transcriptase (RT) inhibitors and soluble CD4, have yielded disappointing clinical benefits.
    • Recent findings highlight the potential of chemokine-mediated suppression of HIV-1 fusion.

    Purpose of the Study:

    • To review the limitations of current HIV-1 therapeutic approaches.
    • To explore novel therapeutic targets and compounds for HIV-1 intervention.
    • To discuss the emerging potential of afferent inhibitors targeting HIV-1 fusion.

    Main Methods:

    • Literature review of existing HIV-1 therapeutic strategies.
    • Analysis of clinical outcomes for preintegrative HIV-1 therapies.
    • Examination of recent research on chemokine-mediated HIV-1 fusion suppression.

    Main Results:

    • Existing preintegrative HIV-1 therapies have shown limited clinical efficacy.
    • Novel therapeutic targets are needed to combat HIV-1 effectively.
    • Chemokine-driven inhibition of HIV-1 fusion presents a promising new direction for treatment development.

    Conclusions:

    • There is a critical need for new therapeutic compounds and targets against HIV-1.
    • Preintegrative therapeutic approaches have not met expectations for clinical benefit.
    • Further development of afferent inhibitors, particularly those targeting HIV-1 fusion via chemokines, is warranted.

    More Related Videos

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing07:18

    High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

    Published on: January 22, 2019

    Related Concept Videos

    Inhibitors of Virion Maturation and Assembly01:19

    Inhibitors of Virion Maturation and Assembly

    As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
    Antiviral Nucleoside Inhibitors01:22

    Antiviral Nucleoside Inhibitors

    Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
    Inhibitors Of Virion Release01:25

    Inhibitors Of Virion Release

    Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...